Enrolment completed for phase 3 of Horizon’s Tyroid eye disease trial

Horizon Pharma has stated that their Phase III trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED) has completed enrolment ahead of schedule. TED is a rare autoimmune disease where the insulin-like growth factor receptor (IGF-1R) is overexpressed on eye tissues, which then leads to local inflammation, orbital fibroblast proliferation and

Continue Reading

Horizon’s Rayos and Amarin’s Vascepa Approved by FDA

The US Food and Drug Administration (FDA) have announced that they have approved Amarin Corp’s heart pill, Vascepa, and Horizon Pharma’s anti-inflammatory, Rayos. The FDA approved Vascepa (icosapent ethyl), formerly known as AMR101, as an addition to diet to reduce triglyceride (levels in adult patients with severe hypertriglyceridemia).  Triglycerides is a blood fat that contributes

Continue Reading